Tag: Canntab

Emblem to Develop Oral Sustained Release Product for Cannabinoids

Emblem Announces Exclusive Agreement with Canntab Therapeutics for Cannabinoid Based Oral Sustained Release Formulation PARIS, Ontario, Oct. 03, 2017 (GLOBE NEWSWIRE) — Emblem Corp. (TSXV:EMC) (EMC.WT) (OTC: EMMBF) (“Emblem”...
- October 3rd, 2017 at 5:12 pm